Article
Genome-wide pharmacogenetic investigation of a hepatic adverse event without clinical signs of immunopathology suggests an underlying immune pathogenesis.
The pharmacogenomics journal - 1 Jun 2008
Kindmark A, Jawaid A, Harbron C G, Barratt B J, Bengtsson O F, Andersson T B, Carlsson S, Cederbrant K E, Gibson N J, Armstrong M, Lagerström-Fermér M E, Dellsén A, Brown E M, Thornton M, Dukes C, Jenkins S C, Firth M A, Harrod G O, Pinel T H, Billing-Clason S M E, Cardon L R, March R E
Abstract excerpt
One of the major goals of pharmacogenetics is to elucidate mechanisms and identify patients at increased risk of adverse events (AEs). To date, however, there have been only a few successful examples of this type of approach. In this paper, we describe a retrospective case-control pharmacogenetic study of an AE of unknown mechanism, characterized by elevated levels of serum alanine aminotransferase (ALAT) during...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.